TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15756004
Drug: IL-6 levels
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 levels less than or equal to the median (4.80 pg/mL)
Study: 15756004
Drug: IL-6 levels
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 levels above the median (4.80 pg/mL)
Study: 15756004
Drug: IL-6 levels
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 levels at a cut point of 13.31 pg/mL
Study: 14507747
Drug: Levocabastine hydrochloride
Normalized name: Levocabastine Hydrochloride
DrugBank: Levocabastine (DB01106)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocabastine hydrochloride 0.05% ophthalmic suspension
Study: 8944829
Drug: Intra-arterially administered
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterially administered losartan (100-3000 ng/kg/min)
Study: 8944829
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered losartan (50 mg once daily for 5 days)
Study: 25688638
Drug: Curcuminoids (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (1500 mg/day in 3 divided doses; n = 19)
Study: 25688638
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules (n = 21)
Study: 25248764
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol 250/50 μg
Study: 20619353
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 μg
Study: 12544718
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (calcium antagonist + beta-blocker)
Study: 10523945
Drug: Intense medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense medical therapy
Study: 2177357
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and vindesine (maintenance chemotherapy: 2 cycles or 4 cycles)
Study: 2177357
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and vindesine (initial chemotherapy)
Study: 7351151
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate (0.08 mg/kg) administered by inhalation, four times a day for seven days
Study: 7351151
Drug: Isoproterenol hydrochloride
Normalized name: Isoproterenol Hydrochloride
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol hydrochloride (2.5 mg) administered by inhalation, four times a day for seven days
Study: 31831561
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of choice (TC; topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Study: 31831561
Drug: Guadecitabine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine and carboplatin (G+C)
Study: 31831561
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of choice (TC)
Study: 31146679
Drug: LVPEG-4 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVPEG-4 (1 L preparation + 1 L required additional fluid)
Study: 31146679
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 L PEG + Asc)
Study: 27869451
Drug: Internet-delivered family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered family-based cognitive-behavioral therapy (FB-CBT)
Study: 27869451
Drug: Clinic-based family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based family-based cognitive-behavioral therapy (FB-CBT)
Study: 27566295
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (AAD)
Study: 24363933
Drug: Current medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current medications only (Control)
Study: 12513901
Drug: Directly administered
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly administered antiretroviral therapy (DAART)
Study: 15156431
Drug: Treatment-adherence support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-adherence support
Study: 11270011
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection technique with 20 mL of ropivacaine 0.75%
Study: 2147517
Drug: paroxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: paroxetine (30 mg/day)
Study: 15780704
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR (225 mg/day)
Study: 31035478
Drug: 140 mL
Normalized name: syringe, disposable, 140 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mL of concentrated beetroot juice (800 mg NO3‐)
Study: 31618208
Drug: Intensive anthelminthic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive anthelminthic treatment
Study: 25902705
Drug: Standard anthelminthic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anthelminthic treatment
Study: 24195204
Drug: Bleeding and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleeding and cupping therapy, applied locally with pricking and cupping once every two days for a total of 8 treatments.
Study: 24195204
Drug: Pregabalin, 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin, 150mg orally, twice a day for a total of 16 days.
Study: 19091808
Drug: Clinical practice
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical practice (first attending clinical physician's treatment)
Study: 16541783
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg(‐1) LCT/MCT propofol
Study: 16541783
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg x kg(‐1) LCT propofol
Study: 16541783
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg x kg(‐1) LCT/MCT propofol
Study: 10792202
Drug: Ceftazidime 40
Normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 40 mg kg‐1 8 hourly by bolus injection
Study: 10792202
Drug: Ceftazidime 4
Normalized name: CEFTAZIDIME 40ML/ML INJ,50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 4 mg kg‐1 h‐1 by constant infusion following a 12 mg kg‐1 priming dose
Study: 9186297
Drug: Tolrestat treatment
Normalized name: tolrestat
DrugBank: Tolrestat (DB02383)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolrestat treatment for 4 weeks in 17 patients
Study: 9186297
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 4 weeks in 17 patients
Study: 3525423
Drug: Viminol R2
Normalized name: viminol
DrugBank: Viminol (DB13353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viminol R2 10 mg
Study: 31008736
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg
Study: 24734891
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (Lis)
Study: 25739586
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (Asp)
Study: 12571667
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (Novasoy, 50 mg daily of isoflavone equivalents)
Study: 1575787
Drug: Monthly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly telephone contact by lay personnel
Study: 27997877
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (0.02 μg kg‐1 min‐1)
Study: 27129091
Drug: Total glucosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of paeony capsule (TGPC) combined with corticosteroids
Study: 10553817
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control of blood glucose with a standardized IV insulin infusion (Group TC)
Study: 6601648
Drug: Rifaprim (RPM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaprim (RPM) - 800 mg SMZ + 160 mg TMP twice daily
Study: 21682350
Drug: DRV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r monotherapy
Study: 25247995
Drug: IPTp-MQ (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPTp-MQ (15 mg/kg)
Study: 22573627
Drug: Lubiprostone (Amitiza)
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone (Amitiza) titrated up to 48 μg/day
Study: 20332739
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg.kg-1 + ketamine 0.5 mg.kg-1
Study: 20332739
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg.kg-1 + ketamine 0.25 mg.kg-1
Study: 12077156
Drug: Cefpodoxime 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime 400 mg
Study: 29624558
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg
Study: 29128558
Drug: 35% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% CO2 inhalation
Study: 10401916
Drug: Compressed air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressed air inhalation
Study: 19046724
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day
Study: 19111075
Drug: TENS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS treatment (5 times per week for 4 weeks, 60 Hz, 100 microS, 25 mA, 20 minutes)
Study: 28125513
Drug: DC vaccine
Normalized name: Recombinant chimeric COVID-19 DC vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC vaccine
Study: 16038528
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy only)
Study: 6603654
Drug: Trimethoprim and
Normalized name: Trimethoprim and derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim and methenamine hippurate (TMP + MH) at 100 + 500 mg b.i.d.
Study: 27829445
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention program integrating HIV-testing and treatment services, ECCD, and nutrition education for caregivers, consisting of nine group-based sessions over 12 weeks.
Study: 2125242
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg once daily)
Study: 6778330
Drug: Oral decongestant
Normalized name: Drixoral Decongestant Non-Drowsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral decongestant (pseudoephedrine hydrochloride)
Study: 6778330
Drug: Decongestant-antihistamine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestant-antihistamine combination (pseudoephedrine hydrochloride and chlorpheniramine maleate)
Study: 17303249
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (control group).
Study: 10336003
Drug: TT virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT virus DNA detection in donors with elevated ALT levels (mean ALT 89.3 U/L)
Study: 10336003
Drug: TT virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT virus DNA detection in donors with normal ALT levels (<= 45 U/L)
Study: 7487244
Drug: Enalaprilat 0.625
Normalized name: enalaprilat 0.625 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 0.625 mg
Study: 7487244
Drug: Enalaprilat 1.25
Normalized name: enalaprilat 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 1.25 mg
Study: 1337458
Drug: Enalaprilat 2.5
Normalized name: enalaprilat 2.5 MG per 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 2.5 mg
Study: 7487244
Drug: Enalaprilat 5
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalaprilat 5 mg
Study: 7487244
Drug: Enalaprilat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (all doses)
Study: 1793725
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with electrically stimulated lymphatic drainage (group B)
Study: 7074796
Drug: Dobutamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine treatment (4-hour infusions weekly for 24 weeks)
Study: 31816038
Drug: Empagliflozin (E)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin (E) 10 mg with Linagliptin (L) 5 mg once daily
Study: 31816038
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 850 or 1000 mg twice daily with Insulin Glargine (I) once daily
Study: 20578537
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/day for 3 days)
Study: 3971104
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous mezlocillin
Study: 30451243
Drug: Bupivacaine 0.125%/fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125%/fentanyl 5.0 μg/mL
Study: 30451243
Drug: Ropivacaine 0.2%/fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2%/fentanyl 5.0 μg/mL
Study: 28224463
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg
Study: 15280147
Drug: Acidic vaginal
Normalized name: Acidic Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic vaginal gel (Miphil)
Study: 1336892
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg administered as a single daily dose for 3 days)
Study: 1336892
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (50 mg/kg/day given b.i.d. for 10 days)
Study: 10647800
Drug: Intravenous methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylnaltrexone
Study: 21978432
Drug: Acellular human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular human dermal matrix augmentation (GraftJacket)
Study: 31173130
Drug: No augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmentation
Study: 23210068
Drug: Midazolam 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.075 mg/kg
Study: 8089543
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg orally three times a day)
Study: 24168840
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy Scale (CTS)
Study: 24168840
Drug: ACE Treatment
Normalized name: Acet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE Treatment Integrity Measure (ATIM)
Study: 21703000
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of CRIS measure
Study: 21703000
Drug: In-person administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person administration of CRIS measure
Study: 14996470
Drug: Non-Aspirin
Normalized name: Non-Aspirin
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Aspirin
Study: 11555764
Drug: Nebulized topical
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized topical saline‐tobramycin solution administered thrice daily for 4 weeks
Study: 11555764
Drug: Saline‐only solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline‐only solution administered thrice daily for 4 weeks
Study: 3327930
Drug: Nicardipine (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.06 mg/min)
Study: 3793001
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg i.v.)
Study: 24668360
Drug: Usual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual daily activities (control group)
Study: 27079993
Drug: Psychiatrists' ability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatrists' ability to provide inpatient and other treatments
Study: 25467772
Drug: Community paramedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community paramedic intervention (regular home visits, health assessments, evidence-based treatments)
Study: 15599642
Drug: Saline, 3
Normalized name: Simply Saline, 3% nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, 3 intra-articular injections of 2 ml saline at the same intervals (10 knees)
Study: 10985480
Drug: IFNalpha 2b
Normalized name: Zenalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha 2b (5 MU sqm/daily)
Study: 10985480
Drug: IFNalpha 2b
Normalized name: Zenalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha 2b plus low-dose AraC
Study: 10985480
Drug: IFNalpha/AraC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha/AraC therapy
Study: 8803740
Drug: Educational videotape
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational videotape about PSA testing and treatment uncertainties (N = 184 in study 1, N = 103 in study 2)
Study: 6424229
Drug: Cimetidine (05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (05 mg/kg/h) after an initial bolus of 1.5 mg/kg
Study: 28865249
Drug: Ultra-low-dose HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose HT (0.5 mg 17β‐estradiol/2.5 mg dydrogesterone)
Study: 28865249
Drug: Standard HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HT (1 mg 17β‐estradiol/5 mg dydrogesterone)
Study: 25617253
Drug: Aripiprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (2 mg per day for days 1-2, 5 mg per day for days 3-4, 10 mg per day for days 5-7, flexibly dosed 5, 10, or 15 mg per day from week 2 to end of study)
Study: 17425158
Drug: Weight-adjusted unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted unfractionated heparin (Heparin-'Biochemie' 25.000 IU/5 ml)
Study: 11807634
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g plus gentamicin 5 mg/kg
Study: 11807634
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g t.i.d. plus gentamicin 5 mg/kg q.d.
Study: 7589023
Drug: Molsidomine 4
Normalized name: molsidomine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 4 mg (2 tablets, given 6 h apart)
Study: 225750
Drug: Diluent control
Normalized name: DILUENT
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluent control solution
Study: 225750
Drug: MSH/ACTH 4-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSH/ACTH 4-10 (30 mg)
Study: 22763473
Drug: Cilnidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (10 mg per day titrated to 20 mg per day)
Study: 22763473
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg per day titrated to 10 mg per day)
Study: 20571820
Drug: Cabergoline 0.5
Normalized name: cabergoline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5 mg twice per week for 8 weeks
Study: 20571820
Drug: Cabergoline 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.25 mg twice per week for 8 weeks
Study: 20571820
Drug: Cabergoline 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.125 mg twice per week for 8 weeks
Study: 20571820
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance treatment (Group I)
Study: 17962596
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pravastatin for 2 weeks followed by 40 mg for 4 weeks
Study: 7575754
Drug: Sustained-release tablet
Normalized name: Oratuss 12 Sustained-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablet (C)
Study: 6972824
Drug: Phenoprocoumon (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoprocoumon (oral anticoagulation) starting on the seventh postoperative day
Study: 29767694
Drug: Serum α-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum α-carotene levels (per log unit (μg/dL) increase)
Study: 29767694
Drug: Serum α-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum α-carotene concentrations at or above the US average (2.92 μg/dL)
Study: 18204133
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg HFA‐BDP once daily (o.d.)
Study: 18204133
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg HFA‐BDP twice daily (b.i.d.)
Study: 16179873
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m) plus treosulfan (2500 or 3000 mg/m2) in cohort 1
Study: 16179873
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m) plus treosulfan (3500 or 4000 mg/m2) in cohort 2
Study: 16179873
Drug: Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 (treosulfan dose <=3000 mg/m2)
Study: 16179873
Drug: Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 (treosulfan dose >=3500 mg/m2)
Study: 12114041
Drug: Fel d
Normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fel d 1 peptides (90 microg in increasing divided doses)